3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Prostatic Neoplasms
30
Prostatic Neoplasms, Castration-Resistant
5
Neoplasm Metastasis
5
Breast Neoplasms
3
Prostate Carcinoma Metastatic to the Bone
2
Neoplasms
2
Hormone Refractory Prostate Cancer
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lung Neoplasms
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Interventions
Iodine-131
11
Thyrotropin Alfa
9
Sorafenib
8
lenvatinib
6
Thyroidectomy
6
vandetanib
5
Sunitinib
5
Saline Solution
5
pazopanib
4
Triiodothyronine
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Vemurafenib
3
Thyroxine
3
Radiotherapy
3
Everolimus
3
Dexmedetomidine
3
Control Groups
3
Cisplatin
3
AZD 6244
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
trametinib
2
tipifarnib
2
romidepsin
2
dabrafenib
2
belinostat
2
Trastuzumab
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Immunohistochemistry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thyroid Neoplasms
×
radium Ra 223 dichloride
×
Clear all
NCT02390934
2019-06-11
RAD-THYR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
13 enrolled